21.11.2016 • TopicsalkoxylationBayerEhrfeld Mikrotechnik

Millireactor in Production

Ehrfeld Mikrotechnik BTS designed, manufactured and supplied a MIPROWA...
Ehrfeld Mikrotechnik BTS designed, manufactured and supplied a MIPROWA production reactor for Shaoxing Eastlake Biochemical (China)

Ehrfeld Mikrotechnik BTS designed, manufactured and supplied a MIPROWA production reactor for Shaoxing Eastlake Biochemical (China) for a production capacity of up to 10,000 t/a. The MIPROWA millireactor with a throughput of about 1m3/h has a nominal width of 400 mm and a length of 7 m and contains about 150 rectangular reaction channels with exchangeable static mixers.

Shaoxing Eastlake Biochemical successfully launched the production plant in Shaoxing mid-September. The continuously operated millireactor replaces more than 20 batch reactors. The fast and strong exothermic reaction is of alkoxylation type. Decision for Miprowa technology was driven by achievable product quality, significantly improved yield, safety aspects and a short return on investment. Eastlake serves the global market segment of agrochemicals based on their active ingredients production.

Scale up started from lab scale by a transition of channel geometries from micrometer to millimeter scale. By this proceeding similar conditions could be achieved in lab scale as later in the channels of the production reactor. Furthermore conclusions could be drawn about the performance parameters of the reactor in production scale. Additional validation experiments in pilot scale with same channel geometries as in production were needed for testing real raw material behavior. Compared to established process technologies a much faster scale-up process could be realized.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.

Photo
19.03.2025 • TopicsStrategy

The Future of Demand for Chemicals

The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.